The Northern Sexual Health Logo




STRIVE trial – New immunotherapy treatment to eliminate HIV

This study is a small first-in-human (called ‘phase I’) study testing the safety, tolerability, and effects of giving a completely new type of therapy to treat HIV infection in adults living with HIV. These therapies called ‘soluble T-cell receptors’ have been made by a pharmaceutical company called Immunocore, to target proteins of the HIV virus with the aim of destroying the infected cells. This type of therapy is already being researched for certain types of cancer and hepatitis B infection. However, the STRIVE study will be the first to test this in people living with HIV.

The study will initially test a very low dose of the new drug. If this is found to be safe and well-tolerated, the dose will carefully be increased and ultimately be given more frequently. 

Study patients will need to be: 

  1. aged 18-65, living with HIV
  2. have been on antiretroviral medicines for less than 7 years
  3. fit and well

This study could lead to a change in the way medicines for HIV infection are given in the future. You will be reimbursed for your time, meals and reasonable travel costs during your participation.

Should you want to learn more about this exciting trial, please e-mail research team at the Hathersage Centre on or call 0161 701 1504 expressing your interest in the STRIVE trial and we will discuss the next steps with you. By contacting us, you are under no obligation to take part in the study. 

Please note that satisfying the criteria above does not guarantee eligibility.

We look forward to hearing from you. Please find more information about the STRIVE study on the Health Research Authority STRIVE web page.

Many thanks,

The Sexual health and ID  Research team

The Northern Sexual Health Footer Logo


NHS Logo

© 2024 The Northern Sexual Health